Relmada Therapeutics (RLMD) Net Cash Flow (2012 - 2026)

Relmada Therapeutics (RLMD) has 15 years of Net Cash Flow data on file, last reported at $6.3 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at $6.3 million, up 331.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.7 million (up 4794.63% YoY), and the FY2025 annual result was -$360486.0, down 53.7% from the prior year.
• Net Cash Flow advanced to $6.3 million in Q1 2026 per RLMD's latest filing, from $2.1 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $23.5 million in Q1 2023 and troughed at -$37.1 million in Q4 2022.
• A 5-year average of -$2.0 million and a median of $31133.0 in 2025 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2022 and 2023: Net Cash Flow slumped 986.8% in 2022, then jumped 4686.45% in 2023.
• A 5-year view of Net Cash Flow shows it stood at -$37.1 million in 2022, then surged by 93.24% to -$2.5 million in 2023, then surged by 194.61% to $2.4 million in 2024, then decreased by 11.01% to $2.1 million in 2025, then soared by 197.33% to $6.3 million in 2026.
• Business Quant data shows RLMD's Net Cash Flow at $6.3 million in Q1 2026, $2.1 million in Q4 2025, and $31133.0 in Q3 2025.